Any disappointment from ISIS Pharmaceuticals (NASDAQ:IONS) recent earnings has been forgotten. While Kynamro may not be selling to the degree investors hoped for, a clincial trial success for a new blood thinner has shares headed higher at the end of the month.
Wall Street is incredibly excited as well, with Piper Jaffray boldly declaring Isis as having the best pipeline in biotech and an obvious takeover target.
In this episode of The Motley Fool's health-care show Market Checkup, analysts David Williamson and Michael Douglass talk Isis' large drug pipeline, its clincal trial success, and why ISIS could be attracting buyout attention.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Isis Pharmaceuticals. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.